Snapshot from Aug 02, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / KCL-286 Alzheimer's mouse study
Tech medical breakthrough

KCL-286 Alzheimer's mouse study

Analysis based on 7 articles · First reported Jul 08, 2026 · Last updated Jul 13, 2026

Sentiment
40
Attention
3
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive preclinical results for KCL-286 could accelerate its development for Alzheimer's, potentially benefiting King s College London's licensing partners. However, further clinical trials are needed before market impact.

Pharmaceutical Biotechnology
Event Summary

Neuroscientists from King s College London found that KCL-286, a drug previously shown safe in Phase 1 trials for spinal cord injury, reduces multiple Alzheimer's disease features in a mouse model. The drug repairs DNA double-strand breaks and reduces inflammation, targeting early disease processes. KCL-286 is a first-in-class, orally bioavailable retinoic acid receptor-beta agonist. The study was published in FEBS Open Bio and funded by the Medical Research Council and the Wellcome Trust.

Entities Involved
per
Jonathan Cran
Professor at King s College London; commented on the drug's potential and Phase 1 safety.
Importance 80.0 Sentiment 40.0
per
Tina Goncalves
Project managed drug development; highlighted disease-modifying potential.
Importance 60.0 Sentiment 40.0
per
Natasha Hill
First author on the study; emphasized multi-target approach.
Importance 60.0 Sentiment 40.0
govactor
United Kingdom — Medical Research Council
Provided funding for the study.
Importance 30.0 Sentiment 0.0
ngo
Wellcome Trust
Provided funding for the study.
Importance 30.0 Sentiment 0.0
Relationships
United Kingdom — Medical Research Council related ↔ Wellcome Trust
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.